Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$47.28M+3315.20%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Justin Schreiber
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 350
- Beta
- 2.04
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -1.65
Financials
Revenue
$47.28M+3315.2%Net Income
$-7.08MEBITDA
$-7.08MFree Cash Flow
$-10.51MEPS (diluted)
$-0.16Shares Outstanding (diluted)
47.79M+589.0%Operating Expenses
$41.68MCash & Debt
$25.14MReturn of Capital
$776.6KRevenue by Segment (annual)
$12.90MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $194.06M | $-7.11M | $-0.23 |
| 2024 | $212.45M | $-18.88M | $-0.53 |
| 2023 | $152.55M | $-20.60M | $-0.70 |
| 2022 | $119.03M | $-45.54M | $-1.57 |
| 2021 | $92.88M | $-60.90M | $-2.27 |
| 2020 | $37.29M | $-58.65M | $-4.24 |
| 2019 | $12.47M | $-3.14M | $-0.36 |
| 2018 | $8.32M | $-1.24M | $-0.14 |
| 2017 | $5.05M | $-1.21M | $-0.14 |
| 2016 | $5.24M | $-1.11M | $-0.16 |
| 2015 | $1.22M | $-62.0K | $-0.01 |
| 2014 | $714.2K | $-460.5K | $-0.08 |
| 2013 | $808.4K | $-268.3K | $-0.05 |
| 2012 | $673.8K | $-445.6K | $-0.08 |
Valuation
LFMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
114Social Signal Score
Mentions (2)
- Newszacks.com·6h ago·Positive
AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares? T expands customer benefits with complimentary LifeMD memberships, offering virtual care, prescriptions and pharmacy services.
View source ↗ - Newsseekingalpha.com·9h ago·Positive
…pite Earnings Miss LifeMD remains a Buy despite disappointing Q2 2026 results, with revenue and EBITDA guidance revised downward and a sequential subscriber decline. LFMD's core business model is profitable at an 88% gross margin, but elevated customer acquisition costs—now 59% of revenue—are pressuring EBITDA. Management is shifting strategy from auction-based marketing to partnerships with manufacturers, employers, and insurers, aiming to reduce CAC and leverage branded GLP-1 therapies.
View source ↗
Earnings
Wed, Nov 11(in 8 weeks)
Consensus estimate $-0.14 per share
Typical surprise -42.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.16 vs $-0.15miss
- Wed, May 6$-0.20 vs $-0.14miss
- Mon, Mar 9$-0.04 vs $-0.01miss
- Mon, Nov 17$-0.10 vs $-0.06miss
- Mon, Aug 4$-0.05 vs $0.18miss
- Tue, May 6$0.01 vs $-0.04beat
Estimates and results for LFMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LFMD officers and directors.
- Bought
- $199k
- Sold
- $5.7m
3 trades
16 trades
- Friedeman Jessicasold
- Alvarez Nicholas Psold
- Schreiber Justinsold
- Schreiber Justinsold
- Benathen Marc Davidsold
- Benathen Marc Davidsold
- Yecies Eric Haroldsold
- Galluppi Stefansold
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LFMD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.